FR20C1014I2 - TREATMENT OF SLEEP-WAKE CYCLE DISORDERS - Google Patents

TREATMENT OF SLEEP-WAKE CYCLE DISORDERS

Info

Publication number
FR20C1014I2
FR20C1014I2 FR20C1014C FR20C1014C FR20C1014I2 FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2 FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2
Authority
FR
France
Prior art keywords
sleep
treatment
wake cycle
cycle disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1014C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of FR20C1014I1 publication Critical patent/FR20C1014I1/fr
Application granted granted Critical
Publication of FR20C1014I2 publication Critical patent/FR20C1014I2/en
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR20C1014C 2005-06-08 2020-04-16 TREATMENT OF SLEEP-WAKE CYCLE DISORDERS Active FR20C1014I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
FR20C1014I1 FR20C1014I1 (en) 2020-06-12
FR20C1014I2 true FR20C1014I2 (en) 2021-04-23

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1014C Active FR20C1014I2 (en) 2005-06-08 2020-04-16 TREATMENT OF SLEEP-WAKE CYCLE DISORDERS

Country Status (16)

Country Link
US (7) US8440715B2 (en)
EP (1) EP1890684B1 (en)
JP (1) JP5024635B2 (en)
KR (1) KR101335941B1 (en)
CN (1) CN101217949B (en)
AU (1) AU2006254899B2 (en)
BR (1) BRPI0613697A2 (en)
CA (1) CA2611713C (en)
DK (1) DK1890684T3 (en)
ES (1) ES2435403T3 (en)
FR (1) FR20C1014I2 (en)
NL (1) NL301037I2 (en)
PL (1) PL1890684T3 (en)
RU (1) RU2417077C2 (en)
TW (2) TW201328689A (en)
WO (1) WO2006133393A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (en) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 Treatment of sleep-wake disorders
EP1893291B1 (en) * 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (en) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * Methods for treating fibromyalgia syndrome.
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
JP6530741B2 (en) 2013-03-13 2019-06-12 エアリアル,バイオファーマ,エルエルシー Treatment of cataplexy
DK3021838T3 (en) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd TREATMENT OF OBESITY
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (en) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 Aminocarbonyl carbamate compound
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (en) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド Treatment of Attention Deficit / Hyperactivity Disorder (ADHD)
TWI637765B (en) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR102513800B1 (en) 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 Solvate form of (R)-2-amino-3-phenylpropyl carbamate
KR102616545B1 (en) * 2016-10-06 2023-12-26 재즈 파마슈티칼즈 아일랜드 리미티드 Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CA3071779A1 (en) * 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (en) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 A composition for treating Kca3.1 channel mediated diseases comprising phenylalkyl carbamate compounds
WO2024102718A1 (en) * 2022-11-07 2024-05-16 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (en) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen NEW CARBAMATES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (en) 1994-09-09 1999-06-15 남창우 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
KR0173862B1 (en) * 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (en) * 1995-04-10 1999-04-01 조규향 O-carbamoyl-phenylalanineol compounds having substituents on phenyl, pharmaceutically useful salts thereof, and preparation methods thereof
ES2170878T3 (en) * 1996-10-10 2002-08-16 Sk Corp O-CARBAMOIL-PHENYLALANINOL COMPOUNDS AND ITS PHARMACEUTICALLY USEFUL SALTS.
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
RS50505B (en) * 2001-02-27 2010-03-02 Ortho-Mcneil Pharmaceutical Inc. Carbamate compounds for use in preventing or treating anxiety disorders
ES2262801T3 (en) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. USE OF A CARBAMATE COMPOUND FOR THE PREVENTION OR TREATMENT OF BIPOLAR DISORDER.
CZ20032299A3 (en) * 2001-02-27 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Medicament for prevention or treatment of motor disorders
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MX2007005172A (en) 2004-10-28 2007-06-22 Sk Corp Shaving razors, and blade subassemblies therefor and methods of manufacture.
KR101335941B1 (en) * 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 Treatment of sleep-wake disorders
EP1893291B1 (en) 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
ATE538784T1 (en) 2005-07-26 2012-01-15 Sk Biopharmaceuticals Co Ltd METHOD FOR TREATING SUBSTANCE-RELATED DISEASES
MX2009003926A (en) 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions.
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (en) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * Methods for treating fibromyalgia syndrome.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102005483B1 (en) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 Thin film transistor array panel and method for repairing the same
JP6530741B2 (en) * 2013-03-13 2019-06-12 エアリアル,バイオファーマ,エルエルシー Treatment of cataplexy

Also Published As

Publication number Publication date
RU2008100019A (en) 2009-07-20
TW201328689A (en) 2013-07-16
US8440715B2 (en) 2013-05-14
WO2006133393A1 (en) 2006-12-14
FR20C1014I1 (en) 2020-06-12
TW200716084A (en) 2007-05-01
US8877806B2 (en) 2014-11-04
US20140350098A1 (en) 2014-11-27
CN101217949A (en) 2008-07-09
BRPI0613697A2 (en) 2011-01-25
PL1890684T3 (en) 2014-05-30
ES2435403T3 (en) 2013-12-19
AU2006254899A1 (en) 2006-12-14
TWI419681B (en) 2013-12-21
CN101217949B (en) 2012-10-17
US20210078943A1 (en) 2021-03-18
EP1890684A1 (en) 2008-02-27
US20170158622A1 (en) 2017-06-08
US9604917B2 (en) 2017-03-28
US11753368B2 (en) 2023-09-12
CA2611713A1 (en) 2006-12-14
DK1890684T3 (en) 2013-10-14
NL301037I1 (en) 2020-04-01
KR20080035565A (en) 2008-04-23
US20090312416A1 (en) 2009-12-17
US20240239740A1 (en) 2024-07-18
EP1890684B1 (en) 2013-08-14
US20130137764A1 (en) 2013-05-30
JP5024635B2 (en) 2012-09-12
CA2611713C (en) 2013-10-01
US20190367448A1 (en) 2019-12-05
NL301037I2 (en) 2020-05-12
AU2006254899B2 (en) 2011-11-24
RU2417077C2 (en) 2011-04-27
US10351517B2 (en) 2019-07-16
KR101335941B1 (en) 2013-12-04
JP2008545795A (en) 2008-12-18

Similar Documents

Publication Publication Date Title
FR20C1014I2 (en) TREATMENT OF SLEEP-WAKE CYCLE DISORDERS
FR21C1063I1 (en) COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
ATE434620T1 (en) DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
FR2912833B1 (en) PANEL FOR ACOUSTIC TREATMENT
FR2882654B1 (en) USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES
DK2056807T3 (en) Treatment of inflammatory diseases
ATE478864T1 (en) HYDANTOINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
FR2901405B1 (en) TREATMENT APPARATUS
FR2876047B1 (en) TREATMENT OF POLLUTANTS BY PHYTOLIXIVIATION
BRPI0815551A2 (en) TREATMENT THROUGH HUCBC OF BETA-AMYLOID DISEASE
BRPI0716466A2 (en) TREATMENT OF SUGAR
FR2928832B1 (en) WRIST ORTHESIS FOR THE TREATMENT OF CARPENTAL CANAL SYNDROME
ATE465150T1 (en) PIPERAZINYL DERIVATIVES SUITABLE FOR THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEPTOR
FR2900336B1 (en) KERATINIC WASHING COMPOSITION AND COSMETIC TREATMENT METHOD USING THE SAME
BRPI0715728A8 (en) treatment of cartilage disorders
FR2884647B1 (en) TREATMENT OF SEMICONDUCTOR PLATES
MA28493B1 (en) Sulfonamides for the treatment of neurodegenerative disorders
FR2943537B1 (en) TREATMENT OF VESTIBULAR NEVITIS BY ACETYL-L-LEUCINE
IL196449A0 (en) Device for physiotherapeutic treatment of diseases of various etiology
FR2922610B1 (en) ACOUSTIC TREATMENT VOLUME FAN
FR2907022B1 (en) MODULAR TREATMENT UNIT
DK1940447T3 (en) TREATMENT OF NEURODEGENRATIVE DISORDERS
ITVR20050112A1 (en) BED FOR MASSAGES
FR2908965B1 (en) COSMETIC ASSEMBLY AND METHOD OF COSMETIC TREATMENT
FR2881346B1 (en) CAPILLARY TREATMENT PROCESS AND USE THEREOF